Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

Exclusion criteria

• . AIDS-defining illness (category C) diagnosed within the last 12 months prior to study entry
• . History of HIV related encephalopathy
• . Active opportunistic infection including active tuberculosis
• . Previous treatment with IL-2 or IL-7 at any time prior to study entry
• . Any planned or probable modification of the anti-retroviral treatment during the first year or the first two cycles of CYT107 Note: in case of product shortage and in absence of viral mutation suspicion or viral blip, a modification of ARV will not be an exclusion criterion
• . Poor compliance on HAART or any other chronic treatment that in the opinion of the investigator will interfere with protocol participation
• . Previous treatment with immuno-modulatory agents such as, systemic corticosteroids, growth factors, immunosuppressive drugs, HIV vaccine, or anti-cancer treatment or hydroxyurea within 3 months prior to study entry
• . Any history of malignancy (except basal carcinoma of the skin) including any hematologic malignancy or AIDS defining malignancy, such as lymphoproliferative disorder or Kaposi's sarcoma Note: Patients with Kaposi's sarcoma limited to the skin that had disappeared while on HAART therapy, and without requiring any other systemic therapy 1 year prior to study entry, will be eligible.